IL129344A0 - Novel integrin receptor antagonists - Google Patents

Novel integrin receptor antagonists

Info

Publication number
IL129344A0
IL129344A0 IL12934497A IL12934497A IL129344A0 IL 129344 A0 IL129344 A0 IL 129344A0 IL 12934497 A IL12934497 A IL 12934497A IL 12934497 A IL12934497 A IL 12934497A IL 129344 A0 IL129344 A0 IL 129344A0
Authority
IL
Israel
Prior art keywords
compounds
receptor antagonists
integrin receptor
cell adhesion
novel integrin
Prior art date
Application number
IL12934497A
Other languages
English (en)
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL129344A0 publication Critical patent/IL129344A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL12934497A 1996-11-27 1997-11-26 Novel integrin receptor antagonists IL129344A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3320896P 1996-11-27 1996-11-27
PCT/US1997/021596 WO1998023608A1 (fr) 1996-11-27 1997-11-26 Nouveaux antagonistes des recepteurs de l'integrine

Publications (1)

Publication Number Publication Date
IL129344A0 true IL129344A0 (en) 2000-02-17

Family

ID=21869102

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12934497A IL129344A0 (en) 1996-11-27 1997-11-26 Novel integrin receptor antagonists

Country Status (12)

Country Link
US (2) US6130231A (fr)
EP (1) EP0944619B1 (fr)
JP (1) JP2001527527A (fr)
AT (1) ATE342262T1 (fr)
AU (1) AU5362998A (fr)
CA (1) CA2272565A1 (fr)
DE (1) DE69736812T2 (fr)
DK (1) DK0944619T3 (fr)
ES (1) ES2270475T3 (fr)
IL (1) IL129344A0 (fr)
PT (1) PT944619E (fr)
WO (1) WO1998023608A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
CA2345210A1 (fr) 1998-11-18 2000-05-25 Prabhakar Kondaji Judhav Nouveaux antagonistes du recepteur de fibrinogene a base d'isoxazoline
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (fr) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Medicaments antagonistes du recepteur de la vitronectine
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
CA2378860A1 (fr) 1999-07-21 2001-02-01 American Home Products Corporation Antagonistes bicycliques selectifs contre l'integrine .alpha.v.beta.3
WO2001024827A2 (fr) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft Inhibiteurs de voie de signalisation de l'endotheline et antagonistes de recepteurs de l'integrine pour traitement combine
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
AU2001272965C1 (en) * 2000-06-21 2006-06-29 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
CA2452478A1 (fr) 2001-08-08 2003-02-20 Bristol-Myers Squibb Pharma Company Imagerie simultanee de perfusion cardiaque et agent d'imagerie cible sur le recepteur de la vitronectine
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US7255875B2 (en) * 2002-01-24 2007-08-14 Barnes-Jewish Hospital Integrin targeted imaging agents
CA2478239A1 (fr) * 2002-03-04 2003-09-18 Medimmune, Inc. Prevention ou traitement de cancer au moyen d'antagonistes de l'integrine alphavbeta3 combines a d'autres agents
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
WO2003086041A2 (fr) * 2002-04-11 2003-10-23 Altarex Medical Corporation Agents de liaison et leur utilisation dans le ciblage de cellules tumorales
AU2003226065B2 (en) 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
WO2004026252A2 (fr) * 2002-09-23 2004-04-01 The Regents Of The University Of Michigan Traitements du gliome
AU2004207002A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
CN1816527A (zh) 2003-06-06 2006-08-09 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US7488739B2 (en) * 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
CA2544678C (fr) * 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulateurs de l'adhesion cellulaire
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
CA2559889A1 (fr) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Traitement cible d'atherosclerose
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
JP5161793B2 (ja) 2006-01-27 2013-03-13 フィブロジェン， インコーポレイテッド 低酸素症誘導因子（ｈｉｆ）を安定化するシアノイソキノリン化合物
CN103497184A (zh) * 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2007127958A2 (fr) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Détection et imagerie d'un tissu cible
US8637469B2 (en) 2006-07-11 2014-01-28 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
LT2068889T (lt) 2006-08-10 2020-02-10 Roy C. Levitt Anakinra, naudojama bronchiolito obliteranso sindromo gydymui
JP2010505770A (ja) * 2006-09-29 2010-02-25 ワシントン ユニバーシティー 血管新生を治療するための併用剤
BRPI0722082A8 (pt) 2006-12-26 2018-03-13 Lantheus Medical Imaging Inc ligantes para imagiologia da inervação cardíaca
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
CN102056485A (zh) * 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
WO2011050175A1 (fr) 2009-10-21 2011-04-28 Sarcode Corporation Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
CA2866556C (fr) 2012-03-09 2020-01-07 Fibrogen, Inc. Composes 4 -hydroxy-isoquinoline comme inhibiteurs d'hif hydroxylase
DK2872488T3 (en) 2012-07-16 2018-10-29 Fibrogen Inc CRYSTALLINIC FORMS OF A PROLYL HYDROXYLASE INHIBITOR
KR102145272B1 (ko) 2012-07-16 2020-08-18 피브로겐, 인크. 이소퀴놀린 화합물의 제조 방법
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2013295706A1 (en) 2012-07-25 2015-02-19 Sarcode Bioscience Inc. LFA-1 inhibitor and polymorph thereof
ES2694297T3 (es) 2013-01-24 2018-12-19 Fibrogen, Inc. Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
HRP20211836T1 (hr) 2013-09-24 2022-03-04 Fujifilm Corporation Novi spoj koji sadrži dušik ili njegova sol, ili njegov metalni kompleks
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
ES2899852T3 (es) 2014-12-17 2022-03-15 Pimco 2664 Ltd Compuestos de N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencenosulfonamida y N-(-4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)-bencenosulfonamida y su uso terapéutico
SG10201902609TA (en) 2015-03-25 2019-04-29 Fujifilm Corp Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW301607B (fr) * 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
CA2155307A1 (fr) * 1993-03-29 1994-10-13 Michael Garth Wayne Composes heterocycliques, inhibiteurs de l'agregation des plaquettes
US5622967A (en) * 1993-04-26 1997-04-22 Sterling Winthrop, Inc. Quinolone carboxamide Calpain inhibitors
WO1994029273A1 (fr) * 1993-06-09 1994-12-22 Smithkline Beecham Corporation Antagonistes bicycliques du fibrinogene
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
EP0799189A4 (fr) * 1994-12-13 1999-03-17 Smithkline Beecham Corp Antagonistes bicycliques du fibrinogene
WO1996026190A1 (fr) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Antagonistes des recepteurs a l'integrine

Also Published As

Publication number Publication date
ES2270475T3 (es) 2007-04-01
ATE342262T1 (de) 2006-11-15
PT944619E (pt) 2007-01-31
CA2272565A1 (fr) 1998-06-04
EP0944619A1 (fr) 1999-09-29
DK0944619T3 (da) 2007-02-05
DE69736812D1 (de) 2006-11-23
US6130231A (en) 2000-10-10
US6358976B1 (en) 2002-03-19
EP0944619B1 (fr) 2006-10-11
JP2001527527A (ja) 2001-12-25
AU5362998A (en) 1998-06-22
DE69736812T2 (de) 2007-08-09
WO1998023608A1 (fr) 1998-06-04

Similar Documents

Publication Publication Date Title
IL129344A0 (en) Novel integrin receptor antagonists
WO1999050249A3 (fr) Antagonistes de l'integrine
IL117645A (en) Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
AU2450197A (en) Alphavbeta3 antagonists
UA74419C2 (uk) Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69720771D1 (en) Integrin antagonist
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
DK1040111T3 (da) Integrinreceptorantagonister
DE69829996D1 (de) Integrin-rezeptor-antagonisten
DE69821132T2 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE60038686D1 (de) Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
EP1246619A4 (fr) Antagonistes des recepteurs de l'urotensine ii
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.
YU38200A (sh) Antagonisti integrinskog receptora
YU38300A (sh) Antagonisti integrinskog receptora